Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US FDA Continues Reviewing Marketing Reports, Will It Punish Scofflaws?

Executive Summary

Six months after submission deadline, about one-third of one-time marketing status reports have been reviewed, agency says.


Related Content

Orange Book Policing May Increase, US FDA's Gottlieb Says
Inside The ANDA Parking Lot
US FDA's Generic Research Projects Appear To Be Opening Way For ANDAs
Outlook For Orange Book Update Not Too Rosy
US FDA's Generic Research May Include EpiPen And Competitors
Drug Sponsors Who Fail To Submit One-Time Marketing Report Face Big Penalty
FDA's Off-Patent, Off-Exclusivity List Draws Few Takers Early On


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts